Affordable Peptides Debate
Caleb discusses the complexities of accessing affordable peptides, particularly for type two diabetics, while highlighting the role of patient assistance programs. He raises concerns about the sustainability and authenticity of alternative sources for these drugs, emphasizing the proprietary nature of certain formulations. The conversation also touches on the balance between patent protection and the ability to replicate effective treatments.In this clip
From this podcast
LONGEVITY with Nathalie Niddam
Episode #77: Semaglutide, A GLP-1 Agonist, Showing Success With Weight Loss and Type 2 Diabetes
Related Questions